Cryo-Cell Q3 2021 revenue down 8% to $7.5M; net income $857K

CRYO CELL INTERNATIONAL INC

2021-Q3 EPS reported $0.33 revenue$21,569,464

Revenue $7.5M vs $8.1M YoY; processing/storage fees $7.3M, public banking $159K.
Net income $857K ($0.10 per share) vs $784K ($0.10) in Q3 2020.
Cost of sales +4%, SG&A +3% due to $167K for Cellular Therapies Institute and $131K Duke patent license expenses.
Recorded $325K decrease in fair value of contingent consideration liability for Cord:Use earn-out.
No guidance provided; company highlights transformation into cellular therapy company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.